Fundraising FoxDeerfield Management Company — 2020 Investments
13 investments dated 2020 · listed companies and verified rows first · show all
GeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.
AI & Machine LearningBiotechDigital HealthHealthtech
Katherine Stueland(CEO)in
Co-investorsOak HC/FT
Element Science is a medical technology company that develops the Jewel, an FDA-approved adhesive-based wearable cardioverter defibrillator designed to protect patients at risk of sudden cardiac arrest.
AI & Machine LearningDigital HealthHardwareHealthtechMedical DevicesSan Francisco, US
Uday N. Kumar(Executive Officer, Director)inUday Kumar(Founder)in
BoardRussell Hirsch(Director)Neil Exter(Director)inKrishna Yeshwant(Director)inWilliam H. Kucheman(Director)
Board seatAndrew ElBardissi· per SEC Form D · $145.6M raise · filed Mar 2020
Co-investorsGV (Google Ventures)Third Rock VenturesQiming Venture Partners
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings.
BiotechDigital HealthMedical DevicesBrisbane, US
Carlos A. Schuler(Executive Officer, Director)inJohn S. Patton(Executive Officer, Director)inRangachari Narasimhan(Executive Officer, Director)Grace Colon(Executive Officer, Director)inMiller Samantha(Executive Officer)
BoardMcCarthy Reenie(Director)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsAsset Management CompanyHealthCapSofinnova Ventures
Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.
Digital HealthHealthtechMedical DevicesMilford, US
Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)inMark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)
Board seatAndrew ElBardissi· per SEC Form D
Co-investorsArboretum VenturesLightstone VenturesRex Health VenturesGenesis Venture CapitalSante Ventures
Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.
BiotechHealthtechMedical DevicesSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)
Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)BlackRockBlackstone Life SciencesClarus Ventures+2 more
cystetic Medicines is a drug development company creating an inhaled dry-powder therapy based on an FDA-approved antifungal compound to treat cystic fibrosis, targeting the roughly 10% of patients not helped by existing modulators.
BiotechHealthtechMedical DevicesChampaign, US
MARTIN BURKE, MD., PH.D.(Director)Dr. Martin D. Burke(Co-founder)Dr. Michael J. Welsh(Co-founder)Dr. Jeffry Weers(Chief Technology Officer)PETER W STEELMAN(Director)inJONATHAN RAMOS(Director)
Co-investorsIllinois Ventures
Humanity provides AI-powered employee scheduling and shift-planning software for frontline and enterprise workforces, automating schedule building, demand forecasting, and labor-cost control.
Future of WorkHR TechSaaSBoston, US
Peter Ward(Executive Officer, Director)inMichael Geer(Director)
Co-investorsPoint NineSaaS CapitalTeam Builder VenturesJumpstart Nova
Octave is a mental health practice platform that connects licensed therapists with patients seeking in-network mental health care.
Digital HealthHealthtechMental HealthSaaSSan Francisco, US
Sandeep Acharya(Founder, CEO)inDavid White(Executive Officer)in
BoardSaurabh Bhansali(Director)inEllie Wheeler(Director)Craig Cimini(Director)
Co-investorsFelicis VenturesGreycroftHealthier CapitalNat TurnerObvious VenturesCompany Ventures+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Perfect HealthSpringtide Child DevelopmentLiquid WireNeomorphReady Responders
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.